Investigation of Cannabis for Pain and Inflammation in Lung Cancer
Status:
Withdrawn
Trial end date:
2021-10-28
Target enrollment:
Participant gender:
Summary
Radiation therapy to the chest is used in late stage lung cancer, and it often leads to
inflammation of the esophagus. The inflammation is expected to occur in about 75% of patient,
and usually begin within a week of starting radiation therapy. The esophagitis causes pain
and difficulty eating. It can also result in stopping or delaying treatment.Radiation therapy
to the chest is used in late stage lung cancer, and it often leads to inflammation of the
esophagus. The inflammation is expected to occur in about 75% of patient, and usually begin
within a week of starting radiation therapy. The esophagitis causes pain and difficulty
eating. The endocannabinoid system is prominent in the gastrointestinal system, and cannabis
has been shown to greatly inhibit inflammation. The compound
(-)-trans-Δ9-tetrahydrocannabinol (Δ-9-THC) has effects that reduce inflammation and pain.
Cannabidiol is a component of cannabis that does not produce subjective or intoxicating
effects, but also has prominent anti-inflammatory properties.
The goal of this study is to perform a double-blind, placebo-controlled study to investigate
the efficacy of cannabis, compared to placebo, in participants undergoing RT (Radiation
Therapy) for lung cancer. Cannabis that has a high concentration of cannabidiol will be used
, which is a cannabinoid that does not change perception or produce intoxication, and low in
Δ-9-THC. In this way, the hope is to maximize the benefit of cannabis, while lowering the
possible side effects of cannabis in medically ill participants.